Genetic predictors of response to treatment with citalopram in depression secondary to traumatic brain injury

Brain Injury

Volumn 24, Issue 7-8, 2010, Pages 959-969

  Lanctt, Krista L ^a   Rapoport, Mark J ^a,b   Chan, Florance ^a   Rajaram, Ryan D ^a   Strauss, John ^d   Sicard, Tricia ^d   McCullagh, Scott ^a,b   Feinstein, Anthony ^a,b   Kiss, Alex ^c   Kennedy, James L ^d   Bassett, Anne S ^a,b,d   Herrmann, Nathan ^a,b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Sunnybrook Health Sciences Centre   (Canada)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Brain derived neurotrophic factor (BDNF); Methylenetetrahydrofolate reductase (MTHFR); Serotonin receptors; Serotonin transporter; Traumatic brain injury; Tryptophan hydroxylase (TPH)

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; SEROTONIN TRANSPORTER; SEROTONIN TRANSPORTER 1A; SEROTONIN TRANSPORTER 2A; TRYPTOPHAN HYDROXYLASE 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DNA POLYMORPHISM; DRUG TOLERABILITY; FEMALE; GENE EXPRESSION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PROMOTER REGION; SEROTONIN TRANSPORTER LINKED PROMOTER REGION; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMNOLENCE; TRAUMATIC BRAIN INJURY; TREATMENT RESPONSE; XEROSTOMIA;

EID: 77953628065     PISSN: 02699052     EISSN: 1362301X     Source Type: Journal    
DOI: 10.3109/02699051003789229     Document Type: Article

References (79)

1. Rogers JM, Read CA. Psychiatric comorbidity following traumatic brain injury. Brain Injury 2007;21:1321-1333.
2. van Reekum R, Cohen T, Wong J. Can traumatic brain injury cause psychiatric disorders? Journal of Neuropsychiatry and Clinical Neurosciences 2000;12:316-327.
3. Jorge RE, Robinson RG, Moser D, Tateno A, Crespo- Facorro B, Arndt S. Major depression following traumatic brain injury. Archives of General Psychiatry 2004;61:42-50.
4. Anstey KJ, Butterworth P, Jorm AF, Christensen H, Rodgers B, Windsor TD. A population survey found an association between self-reports of traumatic brain injury and increased psychiatric symptoms. Journal of Clinical Epidemiology 2004;57:1202-1209.
5. Rapoport MJ, McCullagh S, Shammi P, Feinstein A. Cognitive impairment associated with major depression following mild and moderate traumatic brain injury. Journal of Neuropsychiatry and Clinical Neurosciences 2005;17:61-65.
6. Herrmann N, Rapoport MJ, Rajaram RD, Chan F, Kiss A, Ma AK, Feinstein A, McCullagh S, Lanctot KL. Factor analysis of the Rivermead post-concussion symptoms questionnaire in mild-to-moderate traumatic brain injury patients. Journal of Neuropsychiatry and Clinical Neurosciences 2009;21:181-188.
7. Rapoport MJ, Herrmann N, Shammi P, Kiss A, Phillips A, Feinstein A. Outcome after traumatic brain injury sustained in older adulthood: A one-year longitudinal study. American Journal of Geriatric Psychiatry 2006;14:456-465.
8. Wasserman L, Shaw T, Vu M, Ko C, Bollegala D, Bhalerao S. An overview of traumatic brain injury and suicide. Brain Injury 2008;22:811-819.
9. Salomon K, Clift A, Karlsdottir M, Rottenberg J. Major depressive disorder is associated with attenuated cardiovascular reactivity and impaired recovery among those free of cardiovascular disease. Health Psychology 2009;28:157-165.
10. Silver JM, McAllister TW, Arciniegas DB. Depression and cognitive complaints following mild traumatic brain injury. American Journal of Psychiatry 2009;166:653-661.
11. Jorge RE, Robinson RG, Arndt SV, Starkstein SE, Forrester AW, Geisler F. Depression following traumatic brain injury: A 1 year longitudinal study. Journal of Affective Disorders 1993;27:233-243. (Pubitemid 23114257)
12. Fedoroff JP, Starkstein SE, Forrester AW, Geisler FH, Jorge RE, Arndt SV, Robinson RG. Depression in patients with acute traumatic brain injury. American Journal of Psychiatry 1992;149:918-923.
13. Ashman TA, Cantor JB, Gordon WA, Spielman L, Flanagan S, Ginsberg A, Engmann C, Egan M, Ambrose F, Greenwald B. A randomized controlled trial of sertraline for the treatment of depression in persons with traumatic brain injury. Archives of Physical Medicine and Rehabilitation 2009;90:733-740.
14. Lee H, Kim SW, Kim JM, Shin IS, Yang SJ, Yoon JS. Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury. Human psychopharmacology 2005;20:97-104.
15. Fann JR, Uomoto JM, Katon WJ. Sertraline in the treatment of major depression following mild traumatic brain injury. Journal of Neuropsychiatry and Clinical Neuroscience 2000; 12:226-232.
16. Cassidy J. Fluoxetine: A new serotonergically active antidepressant. Journal of Head Trauma Rehabilitation 1989;4: 67-69.
17. Horsfield SA, Rosse RB, Tomasino V, Schwartz BL, Mastropaolo J, Deutsch SI. Fluoxetine's effects on cognitive performance in patients with traumatic brain injury. International Journal of Psychiatry and Medicine 2002;32: 337-344.
18. Perino C, Rago R, Cicolini A, Torta R, Monaco F. Mood and behavioural disorders following traumatic brain injury: Clinical evaluation and pharmacological management. Brain Injury 2001;15:139-148.
19. Turner-Stokes L, Hassan N, Pierce K, Clegg F. Managing depression in brain injury rehabilitation: The use of an integrated care pathway and preliminary report of response to sertraline. Clinical Rehabilitation 2002;16:261-268.
20. Rapoport MJ, Chan F, Lanctot K, Herrmann N, McCullagh S, Feinstein A. An open-label study of citalopram for major depression following traumatic brain injury. Journal of Psychopharmacology 2008;22:860-864.
21. Busto R, Dietrich WD, Globus MY, Alonso O, Ginsberg MD. Extracellular release of serotonin following fluid-percussion brain injury in rats. Journal of Neurotrauma 1997;14:35-42.
22. Markianos M, Seretis A, Kotsou A, Christopoulos M. CSF neurotransmitter metabolites in comatose head injury patients during changes in their clinical state. Acta Neurochirgica (Wien) 1996;138:57-59.
23. Nayak AK, Mohanty S, Singh RK, Chansouria JP. Plasma biogenic amines in head injury. Journal of Neurological Sciences 1980;47:211-219.
24. Porta M, Bareggi SR, Collice M, Assael BM, Selenati A, Calderini G, Rossanda M, Morselli PL. Homovanillic acid and 5-hydroxyindole-acetic acid in the csf of patients after a severe head injury. II. Ventricular csf concentrations in acute brain post-traumatic syndromes. European Neurology 1975; 13:545-554.
25. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP. Allelic variation of human serotonin transporter gene expression. Journal of Neurochemistry 1996;66: 2621-2624.
26. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274:1527-1531.
27. Hong CJ, Chen TJ, Yu YW, Tsai SJ. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics Journal 2006;6:27-33.
28. Murphy Jr GM, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Archives of General Psychiatry 2004;61:1163-1169.
29. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000;23: 587-590.
30. Serretti A, Kato M, De Ronchi D, Kinoshita T. Metaanalysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Molecular Psychiatry 2007;12:247-257.
31. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, Xu K, Arnold PD, Richter MA, Kennedy JL, et al. Serotonin transporter promoter gain-offunction genotypes are linked to obsessive-compulsive disorder. American Journal of Human Genetics 2006;78:815-826.
32. Wendland JR, Martin BJ, Kruse MR, Lesch KP, Murphy DL. Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Molecular Psychiatry 2006;11:224-226.
33. Minov C, Baghai TC, Schule C, Zwanzger P, Schwarz MJ, Zill P, Rupprecht R, Bondy B. Serotonin-2A-receptor and - transporter polymorphisms: Lack of association in patients with major depression. Neuroscience Letters 2001;303: 119-122.
34. Lemonde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD, Sequeira A, Kushwaha N, Morris SJ, Basak A, et al. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. Journal of Neurosciences 2003;23: 8788-8799.
35. Polesskaya OO, Aston C, Sokolov BP. Allele C-specific methylation of the 5-HT2A receptor gene: Evidence for correlation with its expression and expression of DNA methylase DNMT1. Journal of Neuroscience Research 2006;83:362-373.
36. Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD, Reinalda MS, Slager SL, McGrath PJ, Hamilton SP. A genomewide association study of citalopram response in major depressive disorder. Biological Psychiatry 2010;67:133-138.
37. Zill P, Baghai TC, Zwanzger P, Schule C, Eser D, Rupprecht R, Moller HJ, Bondy B, Ackenheil M. SNP and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene provide evidence for association with major depression. Molecular Psychiatry 2004;9:1030-1036.
38. Daws LC, Munn JL, Valdez MF, Frosto-Burke T, Hensler JG. Serotonin transporter function, but not expression, is dependent on brain-derived neurotrophic factor (BDNF): in vivo studies in BDNF-deficient mice. Journal of Neurochemistry 2007;101:641-651.
39. Castren E, Voikar V, Rantamaki T. Role of neurotrophic factors in depression. Current Opinions in Pharmacology 2007;7:18-21.
40. Duman RS, Monteggia LM. A neurotrophic model for stressrelated mood disorders. Biological Psychiatry 2006;59: 1116-1127.
41. Hwang JP, Tsai SJ, Hong CJ, Yang CH, Lirng JF, Yang YM. The Val66Met polymorphism of the brain-derived neurotrophic- factor gene is associated with geriatric depression. Neurobiology of Aging 2006;27:1834-1837.
42. Oswald P, Del-Favero J, Massat I, Souery D, Claes S, Van Broeckhoven C, Mendlewicz J. No implication of brain-derived neurotrophic factor (BDNF) gene in unipolar affective disorder: Evidence from Belgian first and replication patient-control studies. European Neuropsychopharmacology 2005;15:491-495.
43. Schumacher J, Jamra RA, Becker T, Ohlraun S, Klopp N, Binder EB, Schulze TG, Deschner M, Schmal C, Hofels S, et al. Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biological Psychiatry 2005;58:307-314.
44. Strauss J, Barr CL, George CJ, Devlin B, Vetro A, Kiss E, Baji I, King N, Shaikh S, Lanktree M, et al. Brain-derived neurotrophic factor variants are associated with childhoodonset mood disorder: Confirmation in a Hungarian sample. Molecular Psychiatry 2005;10:861-867.
45. Anttila S, Huuhka K, Huuhka M, Rontu R, Hurme M, Leinonen E, Lehtimaki T. Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression. Journal of Neural Transmissions 2007;114: 1065-1068.
46. Bottiglieri T, Hyland K, Laundy M, Godfrey P, Carney MW, Toone BK, Reynolds EH. Folate deficiency, biopterin and monoamine metabolism in depression. Psychological Medicine 1992;22:871-876.
47. Bjelland I, Tell GS, Vollset SE, Refsum H, Ueland PM. Folate, vitamin B12, homocysteine, and the MTHFR 677C→T polymorphism in anxiety and depression: The Hordaland Homocysteine Study. Archives of General Psychiatry 2003;60:618-626.
48. Gilbody S, Lewis S, Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: A HuGE review. American Journal of Epidemiology 2007;165:1-13.
49. Zintzaras E. C677T and A1298C methylenetetrahydrofolate reductase gene polymorphisms in schizophrenia, bipolar disorder and depression: A meta-analysis of genetic association studies. Psychiatric Genetics 2006;16:105-115.
50. First MB, Spitzer RL, Gibbon M, WIliams J. Structured clinical interview for DSM-IV Axis I disorders-patient edition (SCID-I/P, version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute; 1996.
51. Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine. Definition of mild traumatic brain injury. Journal of Head Trauma Rehabilitation 1993;8:86-87.
52. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-62.
53. Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Archives of General Psychiatry 1988;45:742-747.
54. Sayer NA, Sackeim HA, Moeller JR, Prudic JC, Devanand DP, Coleman EA, Kierksky JE. The relations between observer-rating and self-report of depressive symptomatology. Psychological Assessment 1993;5:350-360.
55. Dias BG, Banerjee SB, Duman RS, Vaidya VA. Differential regulation of brain derived neurotrophic factor transcripts by antidepressant treatments in the adult rat brain. Neuropharmacology 2003;45:553-563.
56. Aydemir O, Deveci A, Taneli F. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: A preliminary study. Progress in Neuropsychopharmacology, Biology and Psychiatry 2005;29:261-265.
57. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada S, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biological Psychiatry 2003;54:70-75. (Pubitemid 36776725)
58. Yoshida K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Progress in Neuropsychopharmacology, Biology and Psychiatry 2002;26:383-386.
59. Tsai SJ, Cheng CY, Yu YW, Chen TJ, Hong CJ. Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. American Journal of Medical Genetics B (Neuropsychiatric Genetics) 2003;123:19-22.
60. Kang R, Chang H, Wong M, Choi M, Park J, Lee H, Jung I, Joe S, Kim L, Kim S, et al. Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. Journal of Psychopharmacology 2009.
61. Bocchio-Chiavetto L, Miniussi C, Zanardini R, Gazzoli A, Bignotti S, Specchia C, Gennarelli M. 5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. Neuroscience Letters 2008;437:130-134.
62. Choi MJ, Kang RH, Lim SW, Oh KS, Lee MS. Brainderived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Research 2006;1118:176-182.
63. Lang UE, Hellweg R, Kalus P, Bajbouj M, Lenzen KP, Sander T, Kunz D, Gallinat J. Association of a functional BDNF polymorphism and anxiety-related personality traits. Psychopharmacology (Berlin) 2005;180:95-99.
64. Sen S, Nesse RM, Stoltenberg SF, Li S, Gleiberman L, Chakravarti A, Weder AB, Burmeister M. A BDNF coding variant is associated with the NEO personality inventory domain neuroticism, a risk factor for depression. Neuropsychopharmacology 2003;28:397-401.
65. Hong CJ, Huo SJ, Yen FC, Tung CL, Pan GM, Tsai SJ. Association study of a brain-derived neurotrophic-factor genetic polymorphism and mood disorders, age of onset and suicidal behavior. Neuropsychobiology 2003;48: 186-189.
66. Licinio J, Dong C, Wong ML. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Archives of General Psychiatry 2009;66:488-497.
67. Ribeiro L, Busnello JV, Cantor RM, Whelan F, Whittaker P, Deloukas P, Wong ML, Licinio J. The brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism and depression in Mexican-Americans. Neuroreport 2007;18: 1291-1293.
68. Gratacos M, Soria V, Urretavizcaya M, Gonzalez JR, Crespo JM, Bayes M, de Cid R, Menchon JM, Vallejo J, Estivill X. A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Pharmacogenomics Journal 2008;8: 101-112.
69. Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ, Herrera DG, Toth M, Yang C, McEwen BS, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxietyrelated behavior. Science 2006;314:140-143.
70. Papakostas GI, Petersen T, Lebowitz BD, Mischoulon D, Ryan JL, Nierenberg AA, Bottiglieri T, Alpert JE, Rosenbaum JF, Fava M. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. International Journal of Neuropsychopharmacology 2005;8:523-528.
71. Denys D, Van Nieuwerburgh F, Deforce D, Westenberg HG. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. Journal of Clinincal Psychiatry 2007;68:747-753.
72. Kim H, Lim SW, Kim S, Kim JW, Chang YH, Carroll BJ, Kim DK. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA: Journal of the American Medical Association 2006;296:1609-1618.
73. Risch N, Herrell R, Lehner T, Liang KY, Eaves L, Hoh J, Griem A, Kovacs M, Ott J, Merikangas KR. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: A meta-analysis. JAMA: Journal of the American Medical Association 2009;301: 2462-2471.
74. Vermeiden M, van den Broek W, Mulder P, Birkenhager T. Influence of gender and menopausal status on antidepressant treatment response in depressed inpatients. Journal of Psychopharmacology 2009;24:497-502.
75. Morishita S, Kinoshita T. Predictors of response to sertraline in patients with major depression. Human Psychopharmacoogyl 2008;23:647-651.
76. Kraft JB, Slager SL, McGrath PJ, Hamilton SP. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biological Psychiatry 2005;58: 374-381.
77. Kraft JB, Peters EJ, Slager SL, Jenkins GD, Reinalda MS, McGrath PJ, Hamilton SP. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biological Psychiatry 2006;61:734-742.
78. Perlis RH, Mischoulon D, Smoller JW, Wan YJ, Lamon- Fava S, Lin KM, Rosenbaum JF, Fava M. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biological Psychiatry 2003;54:879-883.
79. Trivedi MH, Daly EJ. Treatment strategies to improve and sustain remission in major depressive disorder. Dialogues in Clinical Neurosciences 2008;10:377-384.